INTRODUCTION
Topical chemical application used to be thought of as that for local drug dermatological treatment, or perhaps as a cosmetic application. Now bioactive drugs are topically administered for systemic treatment such as hormonal replacement estrogen therapy (Jewelewicz, 1997) . Zondek (1938) reported that if a hormone (oestrone) ointment or hormone oil is rubbed into the shaven skin of the back of a castrated mouse the animal goes into oestrus. He also observed that the topical dose required seven times as much hormone as with subcutaneous injection. The 7 Â difference is topical dose not absorbed through the skin. Feldmann and Maibach (1969) showed estradiol human percutaneous absorption to be 10.6% for 24 hours dose application. The remaining dose was washed off or lost.
Studies in percutaneous absorption have shown that a portion of the topical chemical, generally a few percent of the applied dose, became systemically available. This few percent dose absorbed was sufficient for certain bioactive drugs and led to transdermal drug delivery for systemic application. During the topical drug application period, generally 24 hours, mass balance has shown that the majority of the topically applied dose was still on the skin (Wester and Maibach, 1992) . In essence, an excess of drug is on the skin through the complete topical dosing period. Johnson et al. (1983) showed that in 50 hospitalized patients given tetracycline ointments, creams, lotions, and tinctures containing a fluorescent marker, the topically applied medications did not remain confined to sites of initial application. Yerasi et al. (1997) report an unusual case where a man died of fentanyl poisoning, yet it was his wife who had the fentanyl patches. Wolf et al. (1997) reported childhood poisoning involving transdermal nicotine patches. Lu and Fenske (1999) report dermal transfer of pesticide residues from residential surfaces. Franklin and Geffner (2003) reported a case of pronounced virilization of a 2-year-old boy from a topical testosterone cream being used by his father. Vihtamäki et al. (2004) showed skin contamination by estradiol gel to be a remarkable source of error in plasma estradiol measurements. Topical estradiol and testosterone preparations are available as well as other topical bioactive preparations. This study examines 17b-estradiol human skin in vivo percutaneous absorption, including skin transfer between individuals. (Feldmann and Maibach, 1969) gave topical bioavailability as percent doses absorbed of 7.574. 1, 8.276.3, 6.677.6, and 4.373.8 for A-D, respectively. There were no statistical differences between these groups. The 14 C concentration in the urine samples decreased with half-lives of 28.479.1, 30.8712.0, 29.374.5, and 33.6713 .1 hours, respectively, for Groups A-D. There were no statistical differences between these small groups.
RESULTS
After the 24-hour dosing period, the dosed skin site was washed with soap and water, and the skin was tape stripped on day 7 for residual chemical. The protective cover or sleeve was also analyzed for residual chemical. Table 2 shows that 73-74% applied dose was recovered in the wash from Group A after the 24-hour dose period. There was no residual chemical in day 7 tape strips. Group B wash recovery was 27-29%, and 14-24% transferred to the covering sleeve.
There was no residual dose in the tape strips. Group C wash recovery was 36%, and 13% was recovered from the sleeve. Group D wash recovery was 2.3 and 4.1% recovered from the sleeve. Tape strips were not carried out on Groups C and D because the dosing area could not be defined after the skin rub/contact. Dose accountability for the groups are listed in Table 1 . The results show the majority of the topical dose (Groups A and B) resides on the surface of the skin during the 24-hour dosing period. The dose is available for skin transfer (Group C) and that skin-transferred dose will be absorbed by the recipient person (Group D).
DISCUSSION
Topically applied chemicals reside on the skin for an extended dosing period, and these chemicals can transfer through skin contact with another naive person. This is probably of no consequence for inert chemicals; however, potent topical bioactive chemicals have become available. An example given previously was of topical testosterone on a father which this study has shown could transfer by contact to his son. The testosterone cream was applied without attention to hand washing after application or the possibility of contact transmission to other family members. This began a few months after his son's birth (Franklin and Geffner, 2003) . Different from testosterone which may induce inadvertent effects in immature and female individuals, no relevant risk scenario is currently known from possible transfer of 17b-estradiol.
Our study, using single defined doses of labeled estradiol (about 0.1 mg) and demonstrating absorption rates o10%, was unlikely to produce systemic biological effects in this case. Topical drugs intended for systemic delivery are routinely used over an extended period of time. Our Group A results show that 73-74% protected estradiol dose was still on the skin, and Group B showed 27-29% dose still on the unprotected skin and 14-24% on the clothing (sleeve), probably all still available for absorption. Since the total bioavailability was 7.5% for Group A and 8.2% for Group B, a large portion of active substance is still available for transfer/absorption. This study does not answer the question of how long residual topical drug would be available for Topical bioavailability=urinary excretion (topical dose)/urinary excretion (i.v. dose) Â 100; 51.6% dose excreted after single i.v. dose human (Jewelewicz, 1997). 3 No statistical difference (P40.05). 4 Please note that mass balance is higher where topical dose was better controlled. Cover is non-occlusive/non-skin touching cover over the dosed site.
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Sleeve is disposable cover placed over the arm to stop the spread of radioactivity to the volunteer's clothing and environment.
www.jidonline.org 2191 transfer relative to time on skin, formulation changes, or effect of routine skin washing. Topical bioavailability using cumulative urinary recovery of estradiol in this study was 7.574.1 and 8.276.3% doses for Groups A and B. This compares favorably with the published in vivo estradiol percutaneous absorption of 10.674.9% doses (Feldmann and Maibach, 1969) . This study and the report by Franklin and Geffner (2003) document transfer of estradiol and testosterone. During discussions on sport's doping (BALCO, Olympics), the ''cream'' (testosterone) gets mentioned as a contributing factor. There is the report cited earlier of suspected fentanyl transfer (Yerasi et al., 1997) . This transfer potential will apply to any bioactive topical chemical, and this should not be restricted to drugs. Hazardous environmental chemicals (pesticides, herbicides, pollutants) can topically settle on one individual and be transferred to another person.
This study shows only the one rub/contact sequence for one time period after dosing for one formulation. In the real world, skin contact will occur under a variety of conditions, and each variable will contribute to overall chemical skin transfer. More data are thus warranted. However, the potential for skin transfer of topical bioactive chemicals has been shown in vivo in human volunteers and an awareness of this effect should be heeded. radioactive estradiol was incorporated into the gel. Triplicate aliquots were assayed to determine uniformity of formulation. Use of radioactivity was necessary to distinguish between that estradiol [ 14 C] which was absorbed through the skin and that estradiol which is a natural constituent of the human body.
MATERIALS AND METHODS

Dose formulation
Study design
Group A was to determine topical absorption of [ 14 C]-estradiol under a protective condition during a 24-hour exposure period. The protective non-occlusive cover placed on the dosed area and kept for 24 hours was to protect the dosed site and exclude drug loss. After 24 hours, the dosed site was washed with soap and water and the washing sample was retained for 14 C assay. After topical application, the dosed area was allowed to air dry for 1 hour, then rub and contact the ventral forearm (containing drug) on the ventral forearm of Group D volunteers for 15 minutes. After rubbing, the dosed forearm of Group C volunteers was placed in a sleeve for 24 hours. The volunteers were requested not to touch or wash the dosed area for 24 hours.
Group D. A ventral forearm of Group D volunteers was in contact
with the ventral forearm (containing drug) of Group C volunteers. Skin contact consisted of rubbing five times up and down in one direction (parallel to the axis of the arm), then close contact of skin surfaces for 15 minutes, then rubbing five times up and down in the other direction. After rubbing, the contacted forearm of Group D was placed in a sleeve for 24 hours.
Skin washing and analysis
At 20 hours after dosing, the cover or sleeve was removed and each dosed site was washed using cotton balls (Sherwood Medical, St Louis, MO), Ivory liquid soap (Proctor & Gamble, Cincinnati, OH) and water. The water washing procedure was as follows:
(1) 50% Ivory soap solution (v/v) . (2) Each skin dosed area of Groups A-C volunteers was washed five times. The area outside of the dosed skin on the ventral forearm (called ''non-dosed skin site'') of Group C was also washed. Since the whole skin area on the ventral forearm of Group D volunteers was considered to receive the topical formulation after rubbing, it was divided into two parts, the middle-upper and middle-lower of the ventral forearm. Each part was washed five times using the washing procedure. Individual cotton balls were placed in a borosilicate glass vial containing 5.0 ml of methanol overnight and then 10.0 ml scintillation cocktail was added. Appropriate dilutions were made based on the radioactivity. Radioactivity in these samples was analyzed by liquid scintillation counting to quantify the amount of [
14 C]-estradiol removed from the application site. The cover was also washed five times using the above procedure. The cotton balls were individually placed in a borosilicate glass vial with 10.0 ml scintillation cocktail. Radioactivity of these samples was counted using the liquid scintillation counting.
Skin tape stripping and analysis
The tape stripping on Groups A and B was carried out 168 hours after skin washing to analyze the residual dose. The dosed skin site was stripped with Scotch s cellophane tape 5912 clear (3 M Commercial Supply Division, St Paul, MN) 10 times. These tapes were then individually placed in borosilicate glass vials with 5 ml of methanol overnight, then 10 ml of scintillation cocktail was added, and subsequently assayed for radioactivity by liquid scintillation counting. Tape stripping was not carried out on Groups C and D because the skin rubbing sequence changed the original dosing area.
Radioactivity of sleeve
The sleeve was cut into 20 pieces and individually placed in borosilicate glass vials with 5 ml of methanol overnight, then 10 ml of scintillation cocktail was added, and subsequently assayed for radioactivity by liquid scintillation counting.
Urine sample collection and analysis
Urine samples were collected 0-24, 24-48, 48-72, 72-96, 96-120, 120-144 , and 144-168 hours after dosing. The volume of urine sample was measured and aliquots of urine sample (approximately 20 ml) were kept. Duplicate aliquots of 1.0 ml were used to determine radioactivity. Estradiol topical bioavailability was determined by urinary 14 C excretion and calculated relative to an estradiol human intravenous dose (Feldmann and Maibach, 1969) to determine absolute bioavailability.
Radioactivity assay
All radioactivity measurements were conducted using a Model 1500 Liquid Scintillation Counter (Packard Instruments, Downers Grove, IL). The counter was audited for accuracy using sealed samples of quenched and unquenched standards as detailed by the instrument manual. Background control and test samples were counted in duplicate where possible for 3 or 5 minutes each. Weighed aliquots or urine, skin wash, tape strip, sleeve, and cover wash samples, skin, receptor fluid were mixed directly with Universal Scintillation Cocktail (ICN Biomedicals, Costa Mesa, CA) and analyzed for radioactivity.
Statistical analysis and topical bioavailability
Statistical analysis (t-test, one way analysis of variance) was carried out using SIGMASTAT (SPSS Inc., Chicago, IL). Topical bioavailability was calculated as urinary excretion (topical dose)/urinary excretion (i.v. dose) Â 100. The data of urinary excretion following a single i.v. dose, 51.6% dose excretion, was cited from Feldmann and Maibach (1969) (Jewelewicz, 1997) .
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